NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP China Pharmas » China Sky One Medical,Inc.  1  2  » 
found files: 38
China Sky One Medical,Inc. »05/07/2007 [Company watch]
China Sky One Medical Passes Recent SFDA Inspection

China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that its facilities and products passed a surprise inspection by China State Food and Drug Administration (SFDA) on June 28, 2007. Government officials and industry professionals working for the SFDA inspected the Company\\\\\\\'s production process, including the quality of raw materials, final packaging, consumer instructions, as well as stock-keeping methods...   more»


China Sky One Medical,Inc. »13/11/2007 [Company watch]
China Sky One Medical Reports Third Quarter 2007 Financial Results

3Q07 Revenue Up 148% to $16.8 Million ---- 3Q07 Net Income Up 195% to $5.4 Million HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced financial results for the three month and nine month periods ending September 30, 2007....   more»


China Sky One Medical,Inc. »02/04/2008 [Company watch]
China Sky One Medical, Inc. announced its 2007 revenues

China Sky One Medical, Inc. announced its 2007 revenues climbed 148% to $49.3 million. The company’s net income came in at $15.3 million, which equals $1.15 per share fully diluted and a profit margin of 31%. The company makes and markets traditional Chinese Medicines, most of which are for external use. It also produces diagnostic products....   more»


China Sky One Medical,Inc. »23/05/2008 [Company watch]
China Sky One Receives Approval for Two New Drugs

China Sky One Medical, Inc. (CSKI.OB) was granted SFDA approval for two new drugs: Oxymetazoline Hydrochloride Nasal Drops and Taurine Eye Drops. Oxymetazoline Hydrochloride Nasal Drops are indicated for the treatment of acute and chronic rhinitis, sinusitis and allergic rhinitis. Taurine Eye Drops are approved for the treatment of acute and chronic conjunctivitis. Both rhinitis and conjunctivitis are common in China, especially in colder regions. With the new products, China Sky One now has a portfolio of 98 drugs overall and 49 products that are administered externally. In addition, the company will have submitted a total of 37 additional new drugs to the SFDA by the end of 2008. Because of its distribution network, which China Sky One says is more extensive than the companies that make competitors to the new products, China Sky One expects its new products to quickly capture at least 10% of their respective markets. The company did not make specific revenue predictions. Recently, China Sky One reported first quarter revenues 140% higher than the year-earlier quarter....   more»


China Sky One Medical,Inc. »04/06/2008 [Company watch]
China Sky One Medical, Inc. Receives SFDA Approval for Five Patches

China Sky One Medical, Inc. (Amex: CSY) ("China Sky One Medical", "CSY"), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced today that five of its products have received production permit approvals from the SFDA. Over a year ago, China Sky One Medical began to develop products with large potential global market demand in an effort to expand the Company’s export business. The Company established a R&D team dedicated to the development of these products in February 2006. China Sky One Medical has successfully completed pharmacokinetics studies, clinical studies and the manufacturing process for the following patches: Anti-smoking patch -- breaks down nicotine and other harmful chemical compounds related to cigarette smoking and reduces dependence on cigarettes; Scar patch -- speeds up the healing of the wounds due to trauma and surgeries and reduces the likelihood of developing permanent scars; Migraine patch -- provides quick pain relief for migraine sufferers while alleviating dizziness and nausea; Eye patch -- relaxes the muscles in the retina, which helps to reduce the likelihood of developing myopia; Coronary heart disease patch -- increases blood circulation in coronary arteries, which reduces the incidences of coronary heart disease and myocardial infarction. These patches were developed after extensive research into the market potential by China Sky One Medical’s business development team. The Company has received purchase orders for some products, such as the anti-smoking patch, prior to receipt of the production permit. "Since most of these products utilize extracts from the natural herbs, there are side effects for human consumption. This is especially true for anti-smoking patches. Most of the anti-smoking patches on the market contain nicotine and other chemical compounds," said Mr. Yanqin Liu, Chairman and Chief Executive Officer of China Sky One Medical, "The anti-smoking patches developed by China Sky One are extracts from natural herbs, which have no side effects." This series of patches plays a major role in the Company’s strategy in entering into the global market. The Company currently has ten other products in development targeting the global market....   more»


China Sky One Medical,Inc. »04/06/2008 [Company watch]
China Sky One Medical receives five SFDA approvals

China Sky One Medical, a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products, said five of its products have received production permit approvals from the Chinese SFDA. China Sky One Medical has successfully completed pharmacokinetics studies, clinical studies and the manufacturing process for the following patches: Anti-smoking patch – breaks down nicotine and other harmful chemical compounds related to cigarette smoking and reduces dependence on cigarettes; Scar patch – speeds up the healing of the wounds due to trauma and surgeries and reduces the likelihood of developing permanent scars; Migraine patch – provides quick pain relief for migraine sufferers while alleviating dizziness and nausea; Eye patch – relaxes the muscles in the retina, which helps to reduce the likelihood of developing myopia; Coronary heart disease patch – increases blood circulation in coronary arteries, which reduces the incidences of coronary heart disease and myocardial infarction. The company has received purchase orders for some products, such as the anti-smoking patch, prior to receipt of the production permit....   more»


China Sky One Medical,Inc. »13/06/2008 [Company watch]
China Sky One to acquire Peng Lai Jin Chuang pharma

China Sky One Medical, a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic kit products in China, has signed an agreement to acquire Peng Lai Jin Chuang Company, a newly established pharmaceutical firm that has obtained GMP approval from China’s State Food and Drug Administration (SFDA). Under the terms of the agreement, China Sky One Medical’s wholly-owned subsidiary, Harbin Tian Di Ren Medical Science and Technology, will acquire 100 percent of Jin Chuang's assets for a cash payment of RMB 17 million ($2.5 million) and RMB 32 million ($4.6 million) of China Sky One Medical's common shares. In exchange, China Sky One Medical will obtain Jin Chuang's RMB 70 million ($10.1 million) in assets, which includes franchise, production and operating rights for a portfolio of 20 approved drugs, including drugs for the treatment of colds, cardiovascular disease, and depression. The acquisition is expected to close on or before June 30, 2008. "We expect the synergies that we will realize from this strategic acquisition to make a significant contribution to our profitability in the coming years," said Mr Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "Specifically, Jin Chuang allows us to broaden our product lines and improve our manufacturing capabilities. We have been focused primarily on external use products; however following this acquisition a new pipeline of internal use drugs can enhance our product line. Since Jin Chuang is a newly established company and has not yet started production, we expect it will begin contributing to our profitability at the end of this year,” added Mr Liu....   more»


China Sky One Medical,Inc. »13/06/2008 [Company watch]
China Sky One medical CFO Resigns

HARBIN, China Sky One Medical, Inc., a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic kit products in China, announced today that Mr. Xiaoqing Liao has resigned as a Director, CFO and Board Secretary of China Sky One Medical, Inc. for personal reasons. The resignation was effective June 10, 2008. Mr. Liao joined the Company in March 2008, and had served in various capacities before being appointed to the role of CFO on May 7, 2008. Mr. Yukun Zhang, Financial Manager, will serve as interim CFO, and Ms. Yanwei Zhang, secretary to Mr. Yan-qing Liu, will serve as interim Board Secretary until a successor for Mr. Liao is named. "Mr. Liao has been a valuable member of our team and we appreciate his strong contribution and all he has accomplished, especially his efforts in ensuring the Company's successful migration to the American Stock Exchange," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. "Given our strong growth, we plan to explore our options as we conduct a thorough search for a replacement for Mr. Liao who will meet our rigorous criteria."...   more»


China Sky One Medical,Inc. »13/08/2008 [Company watch]
China Sky One Medical Increase Earnings

China Sky One Medical, Inc. (AMEX: released a very positive Q2 earnings report that also beat analysts’ expectations. Revenues increased 62% to $23.7 million, and net income tjumped 92% to $8.1 million or 50 cents per diluted share. Those results were higher than street estimates of $19.5 million and 37 cents per share. In addition to the numbers, China Sky One took pains to point to a number of company accomplishments during the quarter. The company completed its acquisition of Heilongjiang Tianlong Pharmaceutical, Inc., which gives China Sky One a new manufacturing facility, plus a portfolio of 69 SFDA-approved drugs and more products in the pipeline. During Q2, the company also received SFDA approval for six new drugs and five new patch products. In June, China Sky One also signed an agreement to acquire Peng Lai Jin Chuang Company for a total of $7.1 million. $4.6 million in the purchase price will be paid in stock, and the remaining $2.5 million will be paid in cash. Jin Chuang brings with it a portfolio of 20 approved drugs. In the analysts’ call, China Sky One said that Jin Chuang is a new company that is not yet in production mode. Production is expected to begin before the end of the year, and the acquisition should close in Q3. The company also said that product sales increased 103% year-over-year to $21.9 million, or 92.2% of total revenues. The remainder of the revenues came from contract sales (for other manufacturers). Contract sales decreased 52.3% to $1.8 million. China Sky One has decided to phase out its contract sales business as it builds up its own product offerings. At the end of the quarter, China Sky One had $42.5 million in cash, $44.9 million in working capital, and no debt. After the quarter ended, on July 15, 2008, China Sky One Medical signed an agreement with Harbin Baolong Pharmaceutical Company under which Baolong will distribute China Sky One’s prescription drugs. Prescription drugs now account for 30% of the company’s total product line. The five-year agreement has an estimated value of approximately $9 million. Until now, Baolong has been distributing five of China Sky One’s drugs. China Sky One continues to expect full-year 2008 gross revenue of about $82 million and net income of approximately $26 million, or $1.70 per share, fully diluted. China Sky One is growing quickly, but its stock still sells at bargain prices. It has a P/E ratio of just 11 for the trailing 12-month period. Looking forward, Yahoo says the company is expected to make a profit of $2.46 in 2009, which gives the company a forward P/E of 5.7. China Sky One’s shares moved up 3.6% after releasing its earnings report. The company gained 49 cents to close at $13.99....   more»


China Sky One Medical,Inc. »10/09/2008 [Company watch]
China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully developed 26 new drugs that are currently in clinical trials. Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), a wholly-owned subsidiary of China Sky One Medical, recently completed research and development for the 26 new drugs, which have been submitted to the State Food and Drug Administration (SFDA) in the PRC for approval. "We are excited about the potential for our new drugs currently in clinical trials and we believe that our advanced R&D capabilities will continue to help us expand our market share," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We estimate that the new drugs will account for a 30% increase in our 2009 revenues if production approval is received by the end of the year."...   more»


China Sky One Medical,Inc. »11/09/2008 [Company watch]
China Sky One Medical, Inc. completes the acquisition of Peng Lai Jin Chuang Company

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it completed the acquisition of Peng Lai Jin Chuang Company ("Jin Chuang"). The acquisition was announced on June 12, 2008 and closed on September 5, 2008. Under the terms of the agreement, China Sky One Medical's wholly-owned subsidiary, Harbin Tian Di Ren Medical Science and Technology Company, acquired 100% of Jin Chuang's assets for a cash payment of approximately $7.1 million, consisting of $2.5 million in cash and $4.6 million of China Sky One Medical's common shares. Jin Chuang is a newly established pharmaceutical company that has obtained Good Manufacturing Practice Certification (GMP) approval issued by the country's State Food and Drug Administration (SFDA). Its assets include franchise, production and operating rights to a portfolio of twenty (20) medicines approved by the SFDA for the treatment of colds cardiovascular disease, and depression. "This acquisition complements our business, and we expect to realize greater synergies as we incorporate Jin Chuang's assets and broaden our manufacturing capabilities and product line even further," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "Even though Jin Chuang is a newly established company not begun to manufacture, we expect it will begin to contribute to our profitability at the end of 2008."...   more»


China Sky One Medical,Inc. »29/09/2008 [Company watch]
China Sky 1 Medical Revenues Rise

China Sky One Medical, a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has increased its revenue and earnings guidance for the full-year 2008 period. China Sky One Medical raised its full-year 2008 revenue guidance to $88- $90 million, up from its prior guidance of $81-$83 million, previously announced on August 12, 2008. In addition, the Company now estimates that full-year 2008 net income will be in the range of $27-$28 million, up from its previous estimate of $25.9-$26.6 million. China Sky One Medical expects 2008 gross margin to be approximately 77%. The Company's previous estimate for 2008 gross margin was 78.5%. The increase in the Company's 2008 financial estimates is primarily due to strong results from an advertising campaign for its products that was launched in the second quarter, as well as expected contributions from acquisitions made in 2008. The Company recently started production at Peng Lai Jin Chuang Company ("Jin Chuang"), a newly established pharmaceutical company acquired in June. While Jin Chuang is expected to have a positive impact on 2008 results, it will take time for the Company to ramp up its manufacturing capacity and optimize efficiency in order to achieve large scale production. The Company is also increasing its level of R&D spending in the second half of 2008 to support its growing new product pipeline. "Our business continues to perform well, and our recent acquisitions and the success of a large advertising campaign for our products that we launched in the second quarter are helping to drive our sales," said Mr. Yan-Qing Liu, Chairman, President, and CEO of China Sky One Medicine Inc. "We believe that we will see strong future growth as we continue our strategy of hiring direct territory managers and sales agents to strengthen our distribution channels, as well as increase our R&D to develop a wider range of new and exciting products."...   more»


China Sky One Medical,Inc. »14/10/2008 [Company watch]
China Sky One Medical, announced today that it started production at Peng Lai Jin Chuang Company

Jin Chuang, a subsidiary of China Sky One Medical, develops, manufactures, and distributes pharmaceutical, medicinal and diagnostic products in China. It owns rights to develop and market a portfolio of twenty drugs approved by State Food and Drug Administration (SFDA) of the PRC for the treatment of colds, cardiovascular disease, and depression. Jin Chuang's products include Chinese health remedies such as Oyster Shell Calcium Tablets for the treatment of osteoporosis, and Naftoipidil Dispersible Tablets for the treatment of benign prostatic hyperplasia. China Sky One Medical completed the acquisition of Jin Chuang on September 5, 2008, for approximately $7.1 million, consisting of cash and stock. Production at Jin Chuang is moving smoothly and according to the Company's schedule. "We are pleased to have started production at Jin Chuang, which will allow us to enhance our product line and increase our manufacturing capabilities and profitability," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "We expect Jin Chuang to contribute $3-$5 million to sales in fiscal 2008, and approximately $0.95-$1.55 million in net profit for the year. We believe the acquisition will increase our financial performance even further in 2009 as we scale up our production. As a result of Jin Chuang's contribution, we are reaffirming our previous full year 2008 guidance, which was provided on September 25, 2008."...   more»


China Sky One Medical,Inc. »24/10/2008
China Sky One Signs Distribution Deal for Asthma Patch

China Sky One Medical (CSKI) has signed an agreement with Shaanxi Xintai Pharmaceutical Company to distribute its newly approved Asthma Patch product. China Sky One focuses on OTC patch products for the China market....   more»


China Sky One Medical,Inc. »01/11/2008 [Company watch]
China Sky One Expands into Injected Drugs

China Sky One Medical (CSKI) received SFDA approval for two new products. Sodium ferulate by injection, a TCM found in the root of Angelica sinensis, is indicated for cardiovascular disease. The drug inhibits the gathering of hematoblasts and stretches blood vessels in order to protect cardiac muscles. Doxofylline by injection treats asthma and bronchitis through its bronchodilator effect. It also suppresses coughing....   more»


China Sky One Medical,Inc. »17/11/2008 [Company watch]
Nine New Drugs for China Sky One

China Sky One Medical, Inc. has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million)....   more»


China Sky One Medical,Inc. »05/12/2008 [Company watch]
China Sky One Wins SFDA Approval

China Sky One Medical, announced today that its wholly-owned subsidiary, Heilongjiang Tianlong Pharmaceutical, Inc. obtained production approval from the SFDA in China for a new nasal drop for the treatment of allergic rhinitis and sinusitis....   more»


China Sky One Medical,Inc. »09/12/2008 [Company watch]
China Sky One Medical Obtains Production Rights for Two New Drugs

China Sky One Medical,, announced today that its subsidiary, Peng Lai Jin Chuang Pharmaceutical Company (\"Jin Chuang\"), successfully obtained production approval from the State Food and Drug Administration (SFDA) in China for two of its newly developed drugs....   more»


China Sky One Medical,Inc. »09/12/2008 [Company watch]
China Sky One Medical: Still Priced Low Despite Bright Prospects

China Sky One Medical, Inc (CSKI), as we are reminded almost weekly, is a tornado of activity, acquiring companies and bringing out new products at a pace unmatched in China biopharma....   more»


China Sky One Medical,Inc. »30/12/2008 [Company watch]
China Sky One gets an award for Naftopidil

China Sky One Medical, producer of over-the-counter drugs in Chinahas been awarded the Science and Technology Prize by Shandong province for its Naftopidil Dispersible Tablet...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.